<?xml version="1.0" encoding="UTF-8"?>
<ref id="B87-pharmaceuticals-13-00096">
 <label>87.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Bian</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Zheng</surname>
    <given-names>Z.-H.</given-names>
   </name>
   <name>
    <surname>Wei</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Zhang</surname>
    <given-names>Z.</given-names>
   </name>
   <name>
    <surname>Kang</surname>
    <given-names>W.-Z.</given-names>
   </name>
   <name>
    <surname>Hao</surname>
    <given-names>C.-Q.</given-names>
   </name>
   <name>
    <surname>Dong</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Kang</surname>
    <given-names>W.</given-names>
   </name>
   <name>
    <surname>Xia</surname>
    <given-names>J.-L.</given-names>
   </name>
   <name>
    <surname>Miao</surname>
    <given-names>J.-L.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Meplazumab treats COVID-19 pneumonia: An open-labelled, concurrent controlled add-on clinical trial</article-title>
  <source>medRxiv</source>
  <year>2020</year>
  <pub-id pub-id-type="doi">10.1101/2020.03.21.20040691</pub-id>
 </element-citation>
</ref>
